Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cbd topic
No spam. Unsubscribe anytime.
Senate Approves Narrow Medical CBD Program for Children with Intractable Epilepsy
Summary
After emotional testimony and multiple substitute drafts, the Utah Senate passed a bill allowing neurologist-certified pediatric access to cannabidiol (CBD) products from other jurisdictions, with independent lab testing, registration cards and a University of Utah study; passage was unanimous among present senators.
The Utah Senate passed the ninth substitute to House Bill 105 on the floor after extended debate, creating a narrowly tailored program to allow certain children with intractable epilepsy to possess and use cannabidiol (CBD) products under medical supervision.
Sponsors framed the measure as a targeted medical exception rather than a broad medical-marijuana law. Senator Steve Urquhart opened with the case of a 5-year-old, saying, "Charlotte was having 500 seizures a week," and explained the bill would allow a neurologist to certify an otherwise treatment-resistant child to possess a qualifying CBD extract. The proposal includes patient registration cards, a transfer of limited medical information between physician and the health department, and a partnership with the University of Utah to study outcomes.
Senator Dan Valentine, who introduced substantial technical edits on the floor, said the work focused on safety and data-gathering. The ninth substitute added requirements for independent laboratory testing of extracts produced out-of-state to verify potency and contaminants and made registration cards subject to anti-fraud checks. "We required that this had to have the neurologists record available for the researchers at the University of Utah," Valentine said, noting the bill is structured as a two-year study to evaluate efficacy and safety.
Floor debate acknowledged open questions. Senators raised concerns about potency, long-term effects and program costs; sponsor statements estimated an initial registration fee of around $400, with fees possibly decreasing as enrollment rose. Senator Vickers, who previously tested the literature and chaired related committees, described extensive review and ultimately supported the bill while noting the product is not FDA-approved and potency controls were the chief policy challenge.
Supporters emphasized safeguards: neurologist certification limited to children with intractable epilepsy (defined in the bill as nonresponsive to three or more prior therapeutic modalities), independent lab verification of product quality, a limited registration and monitoring period, and data sharing for research. Opponents urged caution but many ultimately supported the substituted language that tightened testing and tracking provisions.
The ninth substitute passed on a recorded vote of 26 yeas, zero nays, and three absences. Because the bill was amended in the Senate, it will be returned to the House for further consideration of the changes.
Next steps specified in the bill require the Department of Health to implement registration and data-sharing systems and for the University of Utah to begin the outcome-tracking study as specified in the substitute language.
